Dr. Reddy's Laboratories Ltd
corporate_fare Company Profile
Dr. Reddy's Laboratories Ltd (NYSE:RDY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for RDY at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Dr. Reddy's Licensed Drug Fails Phase III Trial, Study Discontinued Due to Futility
- Dr. Reddy's Secures Interim Court Approval to Manufacture and Export Semaglutide
- DOJ Closes FCPA Inquiry Against Dr. Reddy's Without Enforcement Action
- USFDA Inspection at Srikakulam Facility Concludes with Voluntary Action Indicated (VAI) Classification
- SEC Concludes FCPA Investigation into Dr. Reddy's, No Enforcement Action Recommended
Financial Snapshot
Insider Transactions
RDY files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.